Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5608708 | 0.78 | HDAC1 (0.32) | MAPK1PIM2PIM1PIK3CDPIK3CA | |
| SCHEMBL1194064 | 0.76 | KDM4E (0.55) | MAPK1METAP2AXLNUDT1 | |
| SCHEMBL30801230 | 0.75 | MAPK1 (0.58) | MAPK1METAP2ABL1MAPTAXL | |
| SCHEMBL916878 | 0.75 | CCNT1 (0.48) | MAPK1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL3576025 | 0.75 | MAPK1 (0.58) | MAPK1METAP2ABL1MAPTAXL | |
| SCHEMBL7210200 | 0.72 | MAPK1 (0.50) | MAPK1PIM1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL18210595 | 0.72 | AXL (0.44) | MAPK1PIK3CAAXLNUDT1 | |
| SCHEMBL29598957 | 0.71 | NISCH (0.50) | PIM1METAP2ADRA1AP2RX7NISCH | |
| SCHEMBL78566 | 0.71 | NISCH (0.50) | PIM1METAP2ADRA1AP2RX7NISCH | |
| SCHEMBL29454745 | 0.71 | NISCH (0.50) | PIM1METAP2ADRA1AP2RX7NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3291817-B1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10195201-B2 | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180280390-A1 | Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-10-04 | — | — | US | disclosed |
| EP-3291817-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016179059-A1 | HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280390-A1 | Heteroaryl-Pyrimidinone Compounds as PDE2 Inhibitors | PDE2A, PDE12, PDE7B | MAPK1 2003/4885PIM2 567/4885PIM1 2221/4885 |
| US-10195201-B2 | Heteroaryl-pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE7B | MAPK1 2003/4885PIM2 567/4885PIM1 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.